Mitochondria-Targeted Chimeric Peptide for Trinitarian Overcoming of Drug Resistance.
In this report, an amphiphilic mitochondria-targeted chimeric peptide-based drug delivery system (DDS) was designed to overcome drug resistance. In vitro studies revealed that chimeric peptide could encapsulate doxorubicin (DOX) with high efficacy and target tumor mitochondria, realizing controlled release of DOX and in situ photodynamic therapy (PDT) in mitochondria. Importantly, reactive oxygen species (ROS) during PDT significantly disrupted mitochondria, leading to a dramatic decrease of intracellular adenosine 5'-triphophate (ATP). As a result, ATP-dependent efflux of DOX was remarkably inhibited. Trinitarian therapeutic strategy was developed to ablation of drug-resistant cells, that is, (1) enhanced cellular uptake of hydrophobic DOX via encapsulation in DDS, (2) combined chemo-/photodynamic therapies, and (3) suppressed generation of intracellular ATP as well as drug efflux via in situ PDT in mitochondria. This trinitarian strategy may open a new window in the fabrication of subcellular organelle destructive DDS in overcoming drug resistance.
['Han|Kai|K|', 'Zhu|Jing-Yi|JY|', 'Jia|Hui-Zhen|HZ|', 'Wang|Shi-Bo|SB|', 'Li|Shi-Ying|SY|', 'Zhang|Xian-Zheng|XZ|', 'Han|He-You|HY|']
D045744:Cell Line, Tumor D004317:Doxorubicin D016503:Drug Delivery Systems D019008:Drug Resistance, Neoplasm D006801:Humans D008928:Mitochondria D010455:Peptides
drug resistance photodynamic therapy ATP combined therapy mitochondria disruption